Managers

Snap40 takes in $8 mln seed

Edinburgh, Scotland-based Snap40, an AI-enabled healthcare company, has raised $8 million in seed financing. ADV led the round with participation from MMC Ventures.

VC’s new mission in space

QED Investors leads $10.4 mln Series A round for customized impact investing platform OpenInvest

Sleep improvement startup Beddr scores $5.6 mln Series A

Beddr, a sleep improvement startup, has secured $5.6 million in Series A funding. Three Leaf Ventures led the round with participation from other investors that included Stanford-StartX Fund, Delta Dental Washington Seed Fund and I.T. Farm.

Greycroft Partners raises $250 mln fifth venture fund

Greycroft Partners has raised a $250 million fifth venture fund, according to regulatory paperwork. The New York-based firm is led by Dana Settle, Ian Sigalow, Matthew Parker, Mark Terbeek, and John Elton.

HealthCrowd amasses $7.2 mln

San Mateo, California-based HealthCrowd, a healthcare communications platform-as-a-service, has raised $7.2 million in funding. TVC Capital led the round with participation from other investors that included Startup Capital Ventures and Healthy Ventures.

Madaket Health garners $10 mln Series B

Cambridge, Massachusetts-based Madaket Health, a cloud-based, healthcare SaaS platform solution that simplifies administrative data exchange between payers and providers, has raised $10 million in Series B funding. Qiming Venture Partners led the round with participation from Experian Ventures, The PNC Financial Services Group and Salesforce Ventures.

Cereius fetches $6.75 mln

Durham, North Carolina-based Cereius Inc, a biotechnology company focused on treating solid tumor brain metastases, has raised $6.75 million in financing. The investors included BioInnovation Capital.

Inversago Pharma lands $7 mln Series A

Montreal-based Inversago Pharma Inc, a biotech firm, has secured $7 million in Series A financing. Genesys Capital and Amorchem led the round with participation from other investors that included JDRF T1D Fund, Accel-Rx, Anges Québec Capital, Anges Québec and Tarnagulla Ventures.

Alector Inc racks up $133 mln

South San Francisco-based Alector Inc, a biotechnology company focused on developing therapies that harness the immune system to cure neurodegenerative diseases and cancer, has raised $133 million in Series E financing. The investors included Deerfield Management, AbbVie Ventures, Federated Kaufmann Fund, Section 32, Euclidean Capital, Foresite Capital, Lilly Asia Ventures, New Leaf Venture Partners, Polaris Partners, OrbiMed, MRL Ventures, GV and the Dementia Discovery Fund.